| Literature DB >> 32380771 |
Mohamed S Hifnawy1, Hossam M Hassan2, Rabab Mohammed2, Mohamed M Fouda3, Ahmed M Sayed3, Ahmed A Hamed4, Sameh F AbouZid2, Mostafa E Rateb5, Hani A Alhadrami6,7, Usama Ramadan Abdelmohsen8,9.
Abstract
Liquid chromatography coupled with high resolution mass spectrometry (LC-HRESMS)-assisted metabolomic profiling of two sponge-associatedEntities:
Keywords: DNA gyrase; antibacterial; antibiofilm; co-cultivation; phenazine; pyruvate kinase; sponge-associated actinomycetes
Mesh:
Substances:
Year: 2020 PMID: 32380771 PMCID: PMC7281614 DOI: 10.3390/md18050243
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Outline of the procedure used in the present study.
Figure 2Classes of metabolites produced from Micromonospora sp. UR56 and Actinokineospora sp. EG49 axenic and co-cultures.
Figure 3Identified phenazine derivatives in the axenic Micromonospora sp. UR56 culture, and after its co-culture with Actinokineospora sp. EG49. 1: dimethyl phenazine-1,6-dicarboxylate, 2: phencomycin, 3: phenazine-1-carboxylic acid, 4: methyl saphenate, 5: 1-hydroxy methyl-6-carboxy phenazine, 6: griseolutic acid, 7: griseolutin A, 8: aestivophoenin C, 9: N-(2-hydroxyphenyl)-acetamide, and 10: p-anisamide.
Growth inhibition % of 1–3, 9, and 10 at 15 µM against different bacterial strains.
| Tested Compounds |
|
|
|
|
|---|---|---|---|---|
|
| 57.19 ± 1.2 | 19.61 ± 1.5 | 9.93 ± 1.3 | 23.41 ± 1.7 |
|
| 68.87 ± 0.8 | 32.13 ± 1.3 | 11.15 ± 1.4 | 23.25 ± 2.2 |
|
| NA | 1.69 ± 1.2 | 24.34 ± 1.8 | 94.17 ± 2.8 |
|
| 1.1 ± 0.9 | NA | NA | 4.74 ± 1.6 |
|
| 53.17 ± 1.2 | 42.16 ± 1.9 | 19.27 ± 2.5 | 70.23 ± 1.1 |
|
| 99.1 ± 0.7 | 97 ± 1.6 | 99 ± 0.6 | 99.7 ± 0.2 |
NA: no activity.
Figure 4Structure–activity relationship of the induced phenazine derivatives.
Antibiofilm activity of 1–3, 9, and 10 at 2 µM against different bacterial strains.
| Tested Compounds |
|
|
|
|
|---|---|---|---|---|
|
| 50.26 ± 0.4 | 12.10 ± 3.2 | 36.66 ± 2.9 | 18.36 ± 0.9 |
|
| 75.10 ± 2.4 | 18.65 ± 1.6 | 54.07 ± 2.5 | 22.28 ± 1.5 |
|
| NA | NA | 54.67 ± 1.4 | 93.98 ± 2.2 |
|
| 11.47 ± 2.9 | 4.91 ± 1.8 | 34.55 ± 2.6 | 7.39 ± 1.9 |
|
| 61.20 ± 3.7 | 20.29 ± 1.1 | 57.47 ± 3.1 | 73.52 ± 1.3 |
NA: no activity.
Cytotoxic activity of isolated compounds 1–3, 9, and 10 at 2 µM.
| Tested Compounds | WI38 | HCT116 | HePG-2 | MCF7 |
|---|---|---|---|---|
|
| 63.18 ± 3.6 | 85.04 ± 3.9 | 92.06 ± 4.7 | >100 |
|
| 76.30 ± 3.9 | 60.81 ± 3.5 | 76.11 ± 3.9 | 82.24 ± 4.4 |
|
| 51.22 ± 3.2 | 91.27 ± 4.6 | >100 | >100 |
|
| 36.47 ± 2.3 | 14.56 ± 1.2 | 10.16 ± 0.9 | 12.65 ± 1.1 |
|
| >100 | >100 | >100 | >100 |
| Doxorubicin | 6.72 ± 0.5 | 5.23 ± 0.3 | 4.50 ± 0.2 | 4.17±0.2 |
Calculated interactions and affinities of compounds 1–3 with active-site residues of the Staphylococcus Gyr-B and PK.
| Protein Target | Ligand | IC50 (µM) * | Binding Energy (kcal/mol) | Hydrogen Bonding Interactions | Hydrophobic Interactions |
|---|---|---|---|---|---|
|
|
| 19.18 ± 1.69 | −7.6 | ASN-54, GLU-58 | ILE-51, VAL-79 |
|
| 21.28 ± 2.36 | −7.5 | SER-55, ILE-51 | ILE-51, VAL-79 | |
|
| 27.69 ± 1.08 | −7.2 | SER-55, ILE-51 | ILE-51, VAL-79 | |
| Co-crystallized ligand | 0.091 | - | ASP-81, ASN-54 | ILE-51, VAL-79 | |
|
|
| 7.2 ± 0.07 | −7.7 | SER-362A, SER-362B | ALA-358B, ILE-361B, |
|
| 9.3 ± 0.03 | −7.5 | SER-362A, THR-366A, THR-353B, ASN-369A | ALA-358B, ILE-361B, | |
|
| 22.5 ± 0.04 | −6.5 | ASN-369B, THR-353A | ALA-358A, ILE-361A | |
| Co-crystallized ligand | 0.24 | - | SER-362A, SER-362B, ASN-369B, HIS-365A | ALA-358A, ALA-358B ILE-361B, LEU-370A |
* IC50 ± SD (µM).
Figure 5Docking of 1 (A,B), 2 (C,D) and 3 (E,F) within the active site of Staphylococcal Gyr-B. (G,H) The key binding interactions of Gyr-B co-crystallized ligand. The amino acid side chains were depicted in (A,C,E,G) for clarification.
Figure 6Docking of 1 (A,B), 2 (C,D), and 3 (E,F) within the active site of Staphylococcus PK. (G,H) The key binding interactions of the Gyr-B co-crystallized ligand. The amino acid side chains are depicted in (A,C,E,G) for clarification.